Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity
Our findings support the feasibility of individualized lazertinib dosing based on GSTM1 status to reduce toxicity and healthcare costs without compromising effective exposure.
Authors
- Lizza Hendriks (ORCID: https://orcid.org/0000-0002-3521-2535)
- Wouter Heero van Geffen (ORCID: https://orcid.org/0000-0002-5976-0974)
- Anthonie J. van der Wekken (ORCID: https://orcid.org/0000-0001-7175-0026)
- Rob ter Heine (ORCID: https://orcid.org/0000-0003-2185-8201)
- Robin M.J.M. van Geel (ORCID: https://orcid.org/0000-0003-1880-8131)
- B.J.C. van den Bosch (ORCID: https://orcid.org/0000-0002-4067-6203)
- Simon E. Koele (ORCID: https://orcid.org/0000-0002-7011-667X)
- Thijs H. Oude Munnink (ORCID: https://orcid.org/0000-0001-8392-5858)
- Adrianus J. de Langen (ORCID: https://orcid.org/0000-0001-7343-633X)
- Michel M. van den Heuvel (ORCID: https://orcid.org/0000-0002-6372-2153)
Institutions
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- University of Groningen (NL)
- Maastricht University Medical Centre (NL)
- Radboud University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Maastricht University (NL)
- Radboud Institute for Molecular Life Sciences (NL)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1007/s00280-025-04828-y
- Primary Topic
- Protease and Inhibitor Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00